3D Microtissue Screening for Drug Combination Predictability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug screening methods for therapeutic purposes lack systematic approaches to investigate the combinatorial effects of multiple drugs, leading to a high risk of promising drug combinations failing in clinical testing and a need for improved predictability and efficiency in identifying novel drug combinations with sustainable therapeutic efficacy.
Innovation Solution
A method involving a composition selection screen using 3D microtissues derived from cell lines and a validation screen using 3D microtissues from primary patient samples, allowing for high reproducibility and standardization, and enabling the assessment of drug combinations' physiological effects and potential synergies or synergistic effects, thereby reducing the risk of drug combinations failing in clinical trials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional 2D cell-based assays are used for high throughput drug screening, then productivity is improved, but reliability of predicting in vivo efficacy deteriorates
Solution Approach 1:
The patent transitions from conventional 2D cell culture models to 3D microtissue models (spheroids) for drug screening. This dimensional change enables the formation of more physiologically relevant tumor structures with proper cell-cell interactions, extracellular matrix organization, and gradient formation (oxygen, nutrients), thereby improving the reliability of predicting in vivo efficacy while maintaining high throughput screening capabilities through automated imaging and analysis systems
2Device complexity
If drug combinations are screened empirically without systematic approaches, then device complexity is reduced, but reliability of identifying effective combinations deteriorates
Solution Approach 1:
The patent implements a segmented screening strategy that divides the drug combination evaluation process into distinct stages: initial screening of individual drugs, followed by systematic evaluation of drug pairs, triples, and larger combinations. This segmentation allows for manageable complexity while systematically identifying effective combinations through a structured approach that builds upon previous results
Solution Approach 2:
The patent applies preliminary action by first screening individual drugs and identifying active compounds before proceeding to combination screening. This preliminary characterization of single-agent effects provides a foundation for rational combination design, reducing the search space and improving the efficiency of identifying effective drug combinations
3Loss of time
If promising drug combinations are identified without systematic combinatorial screening, then loss of time is reduced, but reliability of clinical success deteriorates
Solution Approach 1:
The patent performs preliminary combinatorial screening in 3D microtissue models before advancing candidates to clinical testing. This preliminary evaluation in a more physiologically relevant system identifies effective combinations early, reducing the time to discovery while improving the reliability of clinical success by filtering out combinations that may not translate to in vivo efficacy
Solution Approach 2:
The patent implements feedback mechanisms where results from 3D microtissue screening inform subsequent combination designs and prioritization. This feedback loop allows for iterative optimization of drug combinations based on empirical data from the 3D models, improving both the speed and reliability of identifying clinically successful combinations
Data Source
AI summary
The present invention relates to a method of characterizing a composition comprising two or more active drug compounds, the method comprising the steps of: a) a composition selection screen (CSS), in which screen a candidate composition comprising two or more active drug compounds is tested against a 3D microtissue derived from one or more cell line, and b) a composition validation screen (CVS), in which screen the candidate composition of step b) is tested against a 3D microtissue derived from a primary patient sample.